Somin Lee

Research Fellow

Somin Lee

Research Fellow

Publications

Hide
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Jain R, Krishnan S, Lee S, Amoozgar Z, Subudhi S, Kumar A, Posada J, Lindeman N, Lei P, Duquette M, Roberge S, Huang P, Andersson P, Datta M, Munn L, Fukumura D
Wnt inhibition alleviates resistance to immune checkpoint blockade in glioblastoma.
Res Sq. 2023;:ePub - PMID: 38234841 - PMCID: PMC10793505 - DOI: 10.21203/rs.3.rs-3707472/v1
Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, Hu ZI, Koay EJ, Tran Cao HS, Jalal PK, Daniel-MacDougall C, Hassan M, Duda DG, Amin HM, Kaseb AO
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Cancers (Basel). 2023;15(19):ePub - PMID: 37835569 - PMCID: PMC10571776 - DOI: 10.3390/cancers15194875
Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO
Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
Oncology. 2023;101(11):730-737 - PMID: 37467732 - PMCID: PMC10614568 - DOI: 10.1159/000531870
Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, Duquette M, Fukumura D, Jain RK
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
J Immunother Cancer. 2023;11(3):ePub - PMID: 36898734 - PMCID: PMC10008211 - DOI: 10.1136/jitc-2022-005583
Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Oncotarget. 2022;13:1314-1321 - PMID: 36473155 - PMCID: PMC9726202 - DOI: 10.18632/oncotarget.28322